Mathes Company Inc. lowered its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 20.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,530 shares of the medical research company’s stock after selling 1,460 shares during the quarter. Mathes Company Inc.’s holdings in Amgen were worth $1,031,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in AMGN. FMR LLC boosted its stake in shares of Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after buying an additional 489,720 shares during the period. BlackRock Inc. raised its holdings in Amgen by 1.9% during the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares in the last quarter. Nordea Investment Management AB raised its holdings in Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after buying an additional 806,119 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Amgen by 3.1% during the second quarter. The Manufacturers Life Insurance Company now owns 3,968,892 shares of the medical research company’s stock valued at $683,562,000 after buying an additional 121,202 shares in the last quarter. Institutional investors and hedge funds own 78.46% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ:AMGN) traded down $0.90 during mid-day trading on Thursday, hitting $181.96. 2,100,000 shares of the stock were exchanged, compared to its average volume of 2,730,000. The company has a market cap of $132,090.00, a PE ratio of 16.44, a price-to-earnings-growth ratio of 2.60 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen, Inc. has a 12 month low of $150.38 and a 12 month high of $191.10.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. During the same period in the prior year, the firm earned $3.02 EPS. The business’s revenue was down .7% on a year-over-year basis. research analysts anticipate that Amgen, Inc. will post 12.71 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.90%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is presently 41.55%.
Amgen announced that its board has approved a share repurchase program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its stock is undervalued.
AMGN has been the topic of several research analyst reports. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research report on Friday, October 27th. Bank of America lifted their target price on Amgen to $210.00 and gave the stock a “buy” rating in a research report on Thursday, October 5th. Barclays lifted their price objective on Amgen from $180.00 to $190.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Royal Bank of Canada assumed coverage on shares of Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price for the company. Finally, Cann reiterated a “buy” rating and issued a $203.00 target price on shares of Amgen in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $190.15.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares in the company, valued at approximately $9,888,326.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,225,765 in the last quarter. 0.19% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Mathes Company Inc. Has $1.03 Million Position in Amgen, Inc. (AMGN)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/amgen-inc-amgn-shares-sold-by-mathes-company-inc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.